stockrow
Friday 6 November 2026
Export NXGL’s income statement to Excel — free account
NexGel, Inc.
NXGL Healthcare Medical Instruments & Supplies
NexGel, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.4 million, up 31.5% from fiscal 2024.
- Revenue
- +27.8%
- EPS
- −344.4%
- Free cash flow
- −432.3%
- Total debt
- +353.8%
Quarter to June 2026, against a year earlier
3.60
0.52
−12.62%
Follow NXGL
Alert me
NexGel, Inc. (NXGL) P/E ratio
NexGel, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 22 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| FEMY Femasys Inc. compare | n/m |
| LUCY Innovative Eyewear, Inc. compare | n/m |
| MLSS Milestone Scientific, Inc. compare | n/m |
| NXGL NexGel, Inc. | n/m |
| BNGO Bionano Genomics, Inc. compare | n/m |
| RVP Retractable Technologies, Inc. compare | n/m |
| NEPH Nephros Inc. compare | 18.0× |
| RGNT Regentis Biomaterials Ltd. compare | — |
| CUPR Cuprina Holdings (Cayman) Limited compare | — |
| Medical Instruments & Supplies industry median | 30.3× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)